2nd Sub. H.B. 130
CANNABINOID RESEARCH

SENATE FLOOR AMENDMENTS AMENDMENT 1 FEBRUARY 22, 2017 2:30 PM

Senator **Evan J. Vickers** proposes the following amendments:

1. Page 4, Lines 103 through 116:

26-59-202. Cannabinoid Product Board -- Duties.

(1) The board shall review any available research related to the human use of a cannabinoid product that:

(a) was conducted under a study approved by an IRB; or

(b) was conducted or approved by the federal government.

{~~(1)~~} **(2)** {~~The~~} **Based on the research described in Subsection (1), the** board shall evaluate the safety and efficacy of cannabinoid products, including:

(a) medical conditions that respond to cannabinoid products;

(b) cannabinoid dosage amounts and medical dosage forms; and

(c) interaction of cannabinoid products with other treatments.

{~~(2)~~} **(3)** Based on the board's evaluation under Subsection {~~(1)~~} **(2)**, the board shall develop guidelines for a physician recommending treatment with a cannabinoid product that includes a list of medical conditions, if any, that the board determines are appropriate for treatment with **a** cannabinoid {~~medicine~~} **product**.

{~~(3)~~} **(4)** The board shall submit the guidelines described in Subsection {~~(2)~~} **(3)** to:

(a) the director of the Division of Occupational and Professional Licensing; and

(b) the Health and Human Services Interim Committee.

{~~(4)~~} **(5)** The board shall report the board's findings before November 1 of each year to the Health and Human Services Interim Committee.